Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions

Abstract

BACKGROUND

Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic relapsing condition in which surgical intervention remains a cornerstone of management despite advances in medical therapy. Surgery plays a definitive role in UC and a complication-directed, bowel-preserving role in CD.

AIM

To provide a comprehensive narrative overview of contemporary surgical management in IBD, focusing on indications, operative strategies, perioperative optimization, postoperative outcomes, and future directions.

METHODS

A narrative review was conducted following the principles of the PRISMA 2009 guidelines. A comprehensive literature search of PubMed/MEDLINE, EMBASE, Scopus, and the Cochrane Library was performed for studies published between January 2000 and December 2024. Relevant original studies, systematic reviews, and meta-analyses addressing surgical interventions in adult IBD patients were included. Evidence was synthesized descriptively.

RESULTS

Surgical indications in UC include medically refractory disease, dysplasia or malignancy, and life-threatening complications, with restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA) representing the standard elective procedure. In CD, surgery is primarily indicated for fibrostenotic and penetrating complications, with emphasis on bowel-sparing approaches such as limited resection and strictureplasty. Minimally invasive and robotic techniques have demonstrated favorable short-term outcomes without compromising long-term results. Perioperative optimization-including nutritional support, steroid minimization, and appropriate integration of biologic therapy-plays a critical role in reducing complications. Postoperative recurrence in CD and pouch-related disorders following IPAA remain major challenges, requiring structured surveillance and multidisciplinary care.

CONCLUSION

Surgery continues to play a vital and evolving role in the management of IBD. Advances in surgical techniques, perioperative care, and integration with medical therapy have improved outcomes and quality of life. Optimal results depend on individualized decision-making within a multidisciplinary framework, with ongoing research needed to refine strategies for recurrence prevention and long-term functional preservation.

Key Words: Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Ileal pouch-anal anastomosis; Bowel-sparing surgery

Core Tip: Surgical intervention remains an essential component of inflammatory bowel disease management despite advances in medical therapy. This narrative review synthesizes contemporary evidence on surgical indications, techniques, perioperative optimization, and postoperative outcomes in ulcerative colitis and Crohn’s disease. Emphasis is placed on bowel-sparing strategies, minimally invasive approaches, and quality-of-life outcomes, highlighting the importance of multidisciplinary, patient-centered decision-making.

INTRODUCTION

Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, immune-mediated disorder characterized by relapsing and remitting inflammation of the gastrointestinal tract. Over recent decades, the epidemiology of IBD has evolved from a predominantly Western disease to a global health burden, with rapidly rising incidence in newly industrialized nations. The chronicity of disease, heterogeneity of phenotypes, and unpredictable clinical course impose a substantial burden on patients, caregivers, and healthcare systems[1].

Despite major advances in medical therapy-including biologics targeting tumor necrosis factor (TNF)-α, integrins, interleukins, and small-molecule agents-surgery remains an integral component of IBD management. Approximately 20%-30% of patients with UC and up to 70%-80% of patients with CD will require at least one surgical intervention during their lifetime. Importantly, surgery in IBD is not synonymous with treatment failure; rather, it represents a complementary and often indispensable modality aimed at disease control, complication management, and improvement of quality of life[2].

The indications, timing, and extent of surgery in IBD have undergone significant evolution. In UC, colectomy offers definitive disease eradication but raises complex decisions regarding restorative procedures such as ileal pouch-anal anastomosis (IPAA) vs permanent end ileostomy. In CD, where surgery is non-curative and recurrence is common, the paradigm has shifted from radical resections to bowel-sparing strategies, including strictureplasty and tailored segmental resections. Parallel advances in minimally invasive surgery, perioperative optimization, biologic therapy integration, and postoperative surveillance have further reshaped surgical outcomes[3].

The expanding surgical literature in IBD is heterogeneous, encompassing randomized trials, observational studies, registry data, technical descriptions, and expert consensus. While several systematic reviews address discrete surgical questions, there remains a need for a comprehensive, integrative narrative synthesis that contextualizes surgical indications, techniques, outcomes, complications, and emerging innovations across the full spectrum of IBD[4].

The aim of this narrative review is to provide an exhaustive and contemporary overview of surgical interventions in IBD, with a comprehensive focus on both UC and CD. This review examines the indications for surgical intervention, outlines established and evolving operative techniques-including restorative procedures, bowel-sparing strategies, and minimally invasive approaches-and discusses perioperative optimization and its interaction with modern medical therapies. In addition, postoperative outcomes and complications, such as disease recurrence and pouch-related disorders, are critically appraised alongside patient-reported quality-of-life outcomes. By synthesizing current evidence and expert perspectives, this review seeks to support surgeons, gastroenterologists, and multidisciplinary IBD teams in informed clinical decision-making and the delivery of patient-centred care.

MATERIALS AND METHODS

This narrative review was conducted in accordance with the principles of the PRISMA 2009 guidelines, with appropriate adaptations for a non-systematic, narrative synthesis. A comprehensive literature search was performed using PubMed/MEDLINE, EMBASE, Scopus, and the Cochrane Library to identify relevant studies published from January 2000 to December 2024. Search terms included combinations of keywords related to IBD, UC, CD, surgical management, colectomy, IPAA, strictureplasty, minimally invasive surgery, postoperative recurrence, pouchitis, and quality of life. Additional articles were identified through manual screening of reference lists of key publications and previously published reviews.

Eligible articles included original research studies, systematic reviews, meta-analyses, and high-quality narrative reviews involving adult patients with IBD and addressing surgical indications, operative techniques, perioperative management, or postoperative outcomes in English language. Isolated case reports, paediatric-only studies and non–peer-reviewed articles were excluded. Potential bias was addressed through several methodological safeguards appropriate for a narrative review. First, a broad and systematic search strategy across multiple major databases was used to minimize selection and publication bias and to ensure inclusion of a wide range of perspectives and study designs. Second, clear eligibility criteria were applied consistently, prioritizing peer-reviewed studies with robust methodology, adequate sample size, and clinical relevance, thereby reducing the risk of selective citation of low-quality evidence.

To limit author selection and confirmation bias, evidence from randomized trials, large observational cohorts, systematic reviews, and meta-analyses was preferentially cited where available, and findings were interpreted in the context of the overall body of literature rather than isolated reports. Areas of conflicting evidence-such as the impact of biologic therapy on postoperative outcomes or the benefits of specific anastomotic techniques-were explicitly acknowledged, and no single study was used to drive conclusions in isolation.

Additionally, surgical outcomes were discussed with attention to disease severity, patient selection, and institutional expertise, which are common sources of confounding in IBD surgical research. Where evidence was limited or heterogeneous, conclusions were framed cautiously, emphasizing trends rather than definitive recommendations. Collectively, these measures aimed to enhance balance, transparency, and interpretative rigor, while recognizing the inherent limitations of narrative reviews.

The evidence was synthesized descriptively, emphasizing consistency of findings, evolution of surgical strategies, and clinical applicability. This approach ensured transparent reporting and methodological rigor while allowing integration of diverse forms of evidence relevant to surgical decision-making in IBD.

RESULTS

The literature search identified studies addressing surgical indications, operative techniques, perioperative optimization, and postoperative outcomes in adult patients with IBD. Evidence consistently demonstrated distinct surgical paradigms for UC and CD. In UC, surgery was primarily indicated for medically refractory disease, dysplasia or malignancy, and acute life-threatening complications, with restorative proctocolectomy and IPAA representing the standard elective approach. In CD, surgical intervention was most commonly required for fibrostenotic and penetrating complications, with increasing emphasis on bowel-sparing strategies such as limited resection and strictureplasty.

Across both diseases, minimally invasive and robotic techniques were associated with favorable short-term outcomes without compromising long-term results. Perioperative optimization-including nutritional support, steroid minimization, and appropriate integration of biologic therapy-was consistently associated with reduced postoperative morbidity. Postoperative recurrence in CD and pouch-related disorders following IPAA remained the principal long-term challenges, underscoring the need for structured surveillance and multidisciplinary postoperative care.

DISCUSSION

Indications in UC

Surgical intervention in UC can be categorized into elective and emergency settings. Elective indications include medically refractory disease despite optimal biologic and immunosuppressive therapy, dysplasia or colorectal cancer (particularly in patients with longstanding colitis), and intolerable medication side effects. The development of colitis-associated dysplasia remains one of the most compelling indications for prophylactic colectomy, as patients with IBD involving at least one-third of the colon carry an increased risk of colorectal cancer that escalates with disease duration. Contemporary surveillance strategies emphasize chromoendoscopy with targeted biopsies, though visible dysplasia that cannot be completely resected endoscopically typically warrants colectomy[4].

Emergency surgical indications include toxic megacolon (colonic dilation exceeding 6 cm with systemic toxicity), free perforation, massive hemorrhage unresponsive to medical intervention, and acute fulminant colitis refractory to intensive medical therapy. Toxic megacolon represents a surgical emergency where delays in operative intervention substantially increase mortality, with perforation rates reaching 50% in some series and mortality rates exceeding 40% when perforation occurs. The cornerstone of surgical management remains early recognition and timely intervention before clinical deterioration[5].

Indications in CD

CD presents unique surgical challenges due to its transmural inflammation, propensity for recurrence, and variable anatomic distribution[6]. Common indications include fibrostenotic obstruction refractory to medical therapy or endoscopic dilation, penetrating complications such as abscesses and fistulae (particularly enterocutaneous, enteroenteric, or enterovesical fistulae), and failure of medical management to achieve or maintain remission. The development of intestinal fibrosis represents a particularly challenging complication, as it occurs in approximately one-third of patients and leads to a high incidence of surgical interventions. Unlike inflammatory strictures that may respond to medical therapy, established fibrotic strictures typically require surgical resection or strictureplasty[7].

Perianal fistulizing CD affects approximately 20% of CD patients and represents a distinct phenotype associated with poor long-term prognosis and significant disability. Complex perianal fistulae require a multidisciplinary approach combining surgical drainage, seton placement, and medical optimization with biologic therapy. The management paradigm has evolved toward combined medical-surgical approaches, with initial seton drainage to control sepsis followed by definitive surgical repair once inflammation is controlled[4,8]. Table 1 summarizes the indications for surgery in UC and CD.

Table 1 Indications for surgery in ulcerative colitis and Crohn’s disease.

Feature	Ulcerative colitis	Crohn’s disease
Main elective indication	Medically refractory pancolitis/proctitis despite optimized biologics	Fibro-stenotic obstruction, penetrating complications, failure of medical therapy
Cancer/dysplasia indication	Visible or high-grade dysplasia, multifocal or nonresectable lesions	Colitis-associated dysplasia in colonic CD; often managed similarly to UC
Emergency indications	Toxic megacolon, perforation, massive hemorrhage, fulminant colitis	Perforation, uncontrolled hemorrhage, fulminant colitis, sepsis from penetrating disease
Typical index operation	Subtotal colectomy with end ileostomy or proctocolectomy with IPAA	Ileocolic resection, segmental resection, or stricturo-plasty

UC: Ulcerative colitis; CD: Crohn’s disease; IPAA: Ileal pouch-anal anastomosis.

Total proctocolectomy with IPAA

IPAA following total proctocolectomy has emerged as the gold standard surgical treatment for UC refractory to medical therapy, offering patients freedom from disease while maintaining intestinal continuity and avoiding permanent stoma. The procedure involves complete removal of the colon and rectum with construction of a neorectum from terminal ileum, most commonly in a J-pouch configuration[9,10].

The evolution of IPAA construction includes two-stage and three-stage approaches. A three-stage procedure is typically reserved for high-risk patients, including those presenting emergently with toxic colitis, severe malnutrition, or significant immunosuppression. The first stage involves subtotal colectomy with end ileostomy, followed by completion proctectomy with IPAA creation and diverting loop ileostomy in the second stage, with ileostomy closure as the final stage. In contrast, the two-stage approach combines proctocolectomy with IPAA creation and diverting ileostomy, followed by ileostomy reversal. Recent evidence demonstrates comparable short- and long-term outcomes between these staging strategies when appropriately selected[11,12].

Functional outcomes following IPAA are generally favorable, with most patients experiencing 5-8 bowel movements daily and acceptable continence. However, complications remain significant, including pouchitis (the most common long-term complication affecting up to 72% of patients at 10 years), anastomotic leaks, strictures, and pelvic sepsis. The Low Anterior Resection Syndrome (LARS) score has demonstrated utility in assessing functional outcomes, with patients experiencing major LARS showing significantly impaired quality of life[13,14].

J-pouch length has emerged as an important technical consideration, with studies demonstrating that shorter pouches (less than 15 cm) are associated with increased late postoperative complications, higher defecation frequency, increased pouchitis rates, and impaired long-term quality of life compared to longer constructions. Implementation of enhanced recovery programs has shown significant benefits in UC patients undergoing IPAA, with lower comprehensive complication index scores, reduced severe complications, shortened hospital stays, and improved long-term quality of life[15,16].

Ileorectal anastomosis

Ileorectal anastomosis (IRA) represents an alternative restorative option that preserves the rectum, offering a less complex surgical alternative with lower perioperative morbidity. Recent systematic reviews have demonstrated favorable long-term functional outcomes in selected UC patients, though the procedure carries ongoing cancer surveillance requirements and potential need for future proctectomy due to refractory proctitis or dysplasia. The cumulative probability of requiring a definitive ileostomy after IRA remains relatively low, with studies demonstrating rates of 1%, 2%, and 6% at 5, 10, and 20 years respectively for UC patients. IRA may be particularly suitable for patients with UC and minimal rectal disease, those desiring pregnancy preservation, or patients with concerns about potential IPAA complications[17,18].

Emergency surgery: Subtotal colectomy

In emergency settings, subtotal colectomy with end ileostomy (and rectal stump management) represents the procedure of choice for toxic megacolon, perforation, or acute severe colitis failing rescue medical therapy. This approach removes the acutely diseased colon while preserving options for future restorative surgery once the patient has recovered. The procedure can increasingly be performed laparoscopically in appropriately selected patients, with evidence supporting similar outcomes to open approaches. Early surgical intervention remains critical, as mortality rates for toxic megacolon with perforation significantly exceed those without perforation (41% vs 8.8% in historical series)[19,20]. Tables 2, 3 and 4 summarizes the surgical options in UC.

Table 2 Key surgical options in ulcerative colitis.

Procedure	Main indication	Advantages	Limitations/risks
Subtotal colectomy with end ileostomy	Emergency toxic megacolon, perforation, severe colitis	Rapid source control; avoids pelvic dissection	Permanent stoma if no later reconstruction; rectal stump issues
Total proctocolectomy + IPAA (J-pouch)	Medically refractory UC; dysplasia/cancer	No colon/rectum; continence preserved; no permanent stoma	Pouchitis, pelvic sepsis, sexual/urinary dysfunction, pouch failure
Total colectomy + ileorectal anastomosis	Mild rectal disease; fertility concerns; high-risk for IPAA	Easier operation, better pelvic nerve preservation	Ongoing rectal disease; cancer surveillance required
Permanent end ileostomy	Unfit for restorative surgery; failed pouch; patient choice	Technically straightforward; reliable symptom control	Body image concerns; stoma complications; appliance dependence

IPAA: Ileal pouch-anal anastomosis; UC: Ulcerative colitis.

Table 3 Ileal pouch-anal anastomosis vs permanent end ileostomy in ulcerative colitis.

Domain	IPAA (ileal pouch-anal anastomosis)	Permanent end ileostomy
Disease control	Removes colon/rectum; pouchitis common long-term	Removes colon/rectum; no pouchitis risk
Bowel function	5-8 BMs/day, some urgency/soilage; improves over time	4-6 stoma emptyings/day; predictable but appliance-dependent
Major complications	Pouchitis, pelvic sepsis, strictures, pouch failure	Parastomal hernia, skin problems, retraction/prolapse
Quality of life (global)	Generally “better or much better” than pre-op in > 80% of patients	Often improved vs pre-op; many report good HRQOL but with body-image issues
Sexual function	Small but real risk of pelvic nerve injury; most maintain function	Less pelvic dissection if rectum spared; function often preserved
Decisional aspects	More complex risk–benefit discussion; strong preference to avoid stoma	Some patients prefer predictable stoma to fear of pouch failure

IPAA: Ileal pouch-anal anastomosis; HRQOL: Health-related quality of life.

Table 4 Two-stage vs three-stage ileal pouch-anal anastomosis.

Feature	Two-stage IPAA	Three-stage IPAA
Typical sequence	Proctocolectomy + IPAA + diverting ileostomy → ileostomy closure	Subtotal colectomy + end ileostomy → completion proctectomy + IPAA + DI → closure
Usual candidates	Medically optimized, lower-risk, stable patients	Acute severe colitis, high-dose steroids, biologic rescue, malnutrition
Short-term morbidity	Comparable to 3-stage in modern series	Comparable; offers safer route in very sick patients
Pouch failure/leak	No significant difference vs 3-stage	No significant difference vs 2-stage
Quality of life after closure	Similar global and functional PROs between strategies	Similar global and functional PROs

PRO: Patient-reported outcomes; IPAA: Ileal pouch-anal anastomosis; DI: Diverting ileostomy.

Bowel resection

Ileocolic resection represents the most commonly performed operation for CD, typically indicated for terminal ileal disease with obstruction or inflammatory complications. The goals of surgery in CD have evolved from complete disease removal toward bowel-sparing approaches that preserve intestinal length while achieving symptomatic relief. This paradigm shift reflects recognition that CD cannot be “cured” surgically and that preserving bowel length minimizes the risk of short bowel syndrome with its devastating metabolic consequences[6,21].

The anastomotic technique following ileocolic resection has been a subject of considerable investigation. Traditional side-to-side stapled anastomosis has been the standard approach, though recent interest has focused on the Kono-S anastomosis-an antimesenteric, functional end-to-end handsewn technique developed in 2011 with the theoretical advantage of creating a wider anastomosis that is more accessible for endoscopic surveillance and dilation[15,22]. Meta-analyses examining Kono-S anastomosis have demonstrated comparable overall morbidity but significantly reduced anastomotic leak rates [odds ratio (OR): 0.34] and reoperation rates (OR: 0.12) compared to conventional anastomoses. However, a recent large nationwide propensity-score matched study from France (KoCo RICCO study) found no significant difference in endoscopic recurrence rates (47.5% Kono-S vs 44.3% conventional side-to-side), suggesting that further research with longer follow-up is necessary to determine potential benefits on surgical recurrence[23].

Strictureplasty

Strictureplasty represents a cornerstone bowel-preserving technique for fibrostenotic CD, allowing symptomatic relief of obstruction while avoiding intestinal resection. The technique has proven particularly valuable in patients with extensive small bowel disease, multiple tandem strictures, or previous resections placing them at risk for short bowel syndrome[24,25].

Several strictureplasty techniques exist, with selection based on stricture length and configuration. The Heineke-Mikulicz strictureplasty represents the most commonly employed technique for short strictures (typically less than 10 cm), involving longitudinal enterotomy across the stricture with transverse closure to widen the lumen. For longer strictures, the Finney strictureplasty (creating a U-shaped configuration) and the side-to-side isoperistaltic strictureplasty (Michelassi procedure) provide alternatives capable of addressing strictures up to 100 cm in length[26,27].

Long-term outcomes demonstrate that strictureplasty remains safe and effective, with acceptable complication rates and durable symptom relief. A recent multicenter audit across three high-volume centers found complications occurring in 35% of patients (with only 8% being Clavien-Dindo grade 3 or higher), and 21% surgical recurrence rate after median follow-up of 54 months. Importantly, continued smoking after strictureplasty significantly increased radiological recurrence rates (53% smokers vs 30% non-smokers), emphasizing the importance of smoking cessation counseling[28,29].

Perianal surgery

Surgical management of perianal fistulizing CD requires careful anatomic assessment with magnetic resonance imaging and examination under anesthesia, combined with coordinated medical therapy. Initial management typically involves abscess drainage and seton placement to control sepsis and maintain fistula tract drainage while avoiding premature closure that could lead to recurrent abscess formation. Setons may be draining (non-cutting) to allow ongoing drainage while medical optimization proceeds, or cutting setons for definitive fistulotomy in selected cases[30,31].

Definitive surgical options include fistulotomy (appropriate only for superficial intersphincteric fistulae with minimal sphincter involvement), endorectal advancement flap, and the ligation of intersphincteric fistula tract (LIFT) procedure. A retrospective cohort study comparing LIFT and advancement flap procedures in CD patients demonstrated clinical healing rates of 89.5% after LIFT and 60% after advancement flap, though radiological healing rates were lower for both approaches (52.6% and 47.6% respectively), highlighting the challenge of achieving complete anatomic healing in CD-related fistulae[8,32].

Newer therapies include darvadstrocel (a suspension of allogeneic adipose-derived mesenchymal stem cells) for treatment-refractory complex perianal fistulae, which has demonstrated efficacy in selected patients and received regulatory approval. Video-assisted anal fistula treatment represents an emerging minimally invasive approach that allows visualization and ablation of the fistula tract under direct endoscopic guidance[33-40]. Table 5 summarizes the surgical options in CD.

Table 5 Common operations in Crohn’s disease.

Operation/technique	Typical indication	Bowel preservation	Key concerns/outcomes
Ileocolic resection	Terminal ileal CD with obstruction or penetrating disease	Limited	High endoscopic recurrence; anastomotic strategy important
Heineke-Mikulicz strictureplasty	Short (< 10 cm) fibrostenotic small-bowel strictures	High	Good long-term patency; avoid in severe inflammation or dysplasia
Finney/michelassi strictureplasty	Long or multiple strictures, risk of short bowel	Very high	Technically demanding; bacterial overgrowth risk in long segments
Kono-S anastomosis	Ileocolic resection where recurrence risk is high	N/A	Similar morbidity; may reduce anastomotic complications and reintervention
Perianal seton drainage	Complex perianal fistulas with abscess/sepsis	N/A	Essential bridge to medical therapy; often long-term seton use

N/A: Not applicable; CD: Crohn’s disease.

Laparoscopic surgery

Laparoscopic surgery has transformed the surgical management of IBD, offering demonstrated advantages including reduced postoperative pain, shorter hospital stays, faster recovery, improved cosmesis, and potentially reduced adhesion formation-a particularly important consideration given that many IBD patients require multiple operations during their lifetime. Systematic reviews and meta-analyses consistently demonstrate comparable or superior outcomes with laparoscopic approaches across multiple IBD operations, including ileocolic resection, subtotal colectomy, and restorative proctocolectomy with IPAA[41].

The burden of postoperative small bowel obstruction-a significant concern in patients undergoing multiple abdominal operations-does not appear to be changed with laparoscopic compared to open approaches, though most cases occur in the early postoperative period, particularly before ileostomy reversal. Conversion rates from laparoscopic to open surgery have decreased with increasing experience, with contemporary audits demonstrating rates significantly below historical standards[29,42].

Robotic surgery

Robotic-assisted surgery represents the newest evolution in minimally invasive IBD surgery, offering potential advantages including enhanced three-dimensional visualization, superior instrument articulation, tremor filtration, and improved ergonomics for the surgeon. A recent systematic review and meta-analysis specifically examining robotic vs laparoscopic colorectal resections in IBD patients (encompassing 5566 patients across 11 studies) found that robotic platforms were associated with significantly lower overall postoperative complication rates compared to laparoscopic surgery, though operative time was significantly longer[43,44].

Specific advantages of robotic surgery appear most pronounced in technically challenging operations, including those involving deep pelvic dissection for rectal operations. A study comparing robotic ileocecal resection in CD patients demonstrated feasibility regardless of disease phenotype, with comparable outcomes to laparoscopic approaches and higher rates of intracorporeal anastomosis. Newer robotic platforms, including the Medtronic Hugo™ RAS system, have shown promising results in IBD surgery with comparable perioperative outcomes to established laparoscopic approaches[3]. Table 6 summarizes the surgical options in IBD.

Table 6 Laparoscopic vs robotic vs open inflammatory bowel disease surgery.

Aspect	Open surgery	Laparoscopic surgery	Robotic surgery
Incision/access	Midline laparotomy	Multiple small ports	Multiple robotic ports; articulated instruments
Postoperative pain	Highest	Reduced vs open	Similar or slightly less vs laparoscopy in some series
Length of stay	Longest	Shorter vs open	Comparable to laparoscopy; sometimes shorter in complex pelvic cases
Conversion to open	N/A	Low but present	Very low in expert centers; longer operative time
Cost/resources	Lowest direct device cost	Moderate	Highest device and OR cost

N/A: Not applicable; OR: Odds ratio.

Preoperative risk factors

Optimal perioperative management significantly impacts surgical outcomes in IBD patients. Key modifiable risk factors include malnutrition (present in a substantial proportion of IBD patients requiring surgery), anemia, active infection or abscess, corticosteroid use, and smoking. Preoperative optimization protocols aim to address these factors before elective surgery to minimize postoperative complications[44-46].

Nutritional optimization is particularly important, as malnutrition (often assessed using the Malnutrition Universal Screening Tool-MUST) and hypoalbuminemia are strongly associated with postoperative complications and extended length of stay. Enteral or parenteral nutritional support may be indicated for severely malnourished patients, potentially delaying surgery until nutritional status improves[47,48].

Corticosteroid use within 30 days of surgery represents a significant risk factor for infectious complications and impaired wound healing, with systematic reviews demonstrating increased postoperative infection rates (OR 1.70). Current guidelines recommend weaning corticosteroids to the lowest possible dose before elective surgery, ideally to less than 20 mg prednisolone equivalent daily[31,49].

Biologic therapy and surgical risk

The impact of biologic medications on surgical outcomes has been extensively investigated given their widespread use in IBD patients presenting for surgery. Current evidence regarding anti-TNF agents (infliximab, adalimumab) is mixed, though most large studies and meta-analyses suggest that anti-TNF exposure does not significantly increase overall postoperative complications when controlling for disease severity and other risk factors. A large French multicenter study examining 1201 CD patients undergoing intestinal resection found overall complication rates of 26.4%, with no significant differences between patients exposed to anti-TNF agents (25.1%), ustekinumab (34.7%), vedolizumab (29.8%), or no biologics (26.1%) after propensity score adjustment[50].

Therapeutic drug monitoring data suggest that detectable serum concentrations of biologics are not associated with increased postoperative complications following abdominal procedures in IBD, providing reassurance that surgery need not be delayed for biologic washout periods[5,51].

Table 7 summarizes the comparison of early surgery vs prolonged medical therapy in localized ileocaecal CD.

Table 7 Early surgery vs prolonged medical therapy in localized ileocaecal Crohn’s disease.

Aspect	Early ileocolic resection	Prolonged/optimized medical therapy (e.g., anti-TNF)
Primary aim	Rapid symptom control and removal of diseased segment	Long-term inflammation control and bowel preservation
Short-term outcomes	Faster symptom relief; fewer steroids; good QoL	Avoids surgical risk initially; some avoid surgery long-term
Long-term surgery need	Many will need further surgery over time	Substantial proportion ultimately require surgery
Strategy implications	Favored for stricturing/penetrating localized disease in fit patients	Favored when extensive small bowel involvement or high surgical risk

TNF: Tumor necrosis factor; QoL: Quality of life.

Venous thromboembolism prophylaxis

Venous thromboembolism (VTE) represents a significant cause of morbidity and mortality in IBD patients, who carry approximately twice the risk of VTE compared to the general population. This risk is compounded during active inflammation, hospitalization, and particularly following surgery. Current guidelines recommend pharmacological thromboprophylaxis for all IBD patients undergoing major abdominal-pelvic surgery, both during hospitalization and as extended post-discharge prophylaxis in high-risk patients[52].

A large multicenter study from the NSQIP IBD collaborative examining VTE prophylaxis practice patterns found that clot rates differed significantly by chemoprophylaxis strategy, with enoxaparin associated with lower clot rates than unfractionated heparin both before discharge (0.57% vs 2.1%) and as extended prophylaxis (0.63% vs 1.4% with no extended prophylaxis). Importantly, chemoprophylaxis strategies were not associated with increased bleeding complications. Risk stratification models incorporating preoperative systemic inflammatory response syndrome and extended resections have been developed to identify patients at highest VTE risk[53,54].

Postoperative recurrence remains the Achilles’ heel of surgical management in CD, with endoscopic recurrence occurring in 35%-85% of patients within the first postoperative year. The Rutgeerts score represents the standard endoscopic classification for postoperative recurrence, assessed at colonoscopy typically performed 6-12 months following ileocolic resection. The modified Rutgeerts score differentiates i2a (lesions confined to the anastomosis) from i2b (neoterminal ileal lesions), though meta-analysis of individual patient data found no significant difference between these subcategories regarding clinical or surgical postoperative recurrence, suggesting the same treatment strategy could be applied to all patients classified as i2[55].

Risk factors for postoperative recurrence include smoking (the most consistently identified modifiable risk factor), penetrating disease phenotype, prior resections, perianal disease, and extensive small bowel resection. The impact of e-cigarettes and heat-not-burn tobacco on postoperative recurrence has recently been examined, with a multicenter international study demonstrating significantly higher recurrence rates in all smoking groups compared to non-smokers (69.4% traditional cigarettes, 63.9% heat-not-burn tobacco, 60.6% e-cigarettes vs 40.8% non-smokers), including patients receiving pharmacological prophylaxis[26,56].

Prevention strategies include postoperative biologic prophylaxis, with evidence supporting early initiation of anti-TNF therapy within 4 weeks following ileocolic resection as associated with reduced postoperative recurrence. Ustekinumab has emerged as a promising option for treating established postoperative recurrence, achieving endoscopic success in patients who developed recurrence despite conventional therapy[37,40,45,57]. Table 8 summarizes the risk factors for postoperative recurrence in CD.

Table 8 Risk factors for postoperative recurrence in Crohn’s disease.

Risk factor	Effect on recurrence
Active cigarette smoking	Strongest modifiable predictor; higher endoscopic and surgical recurrence
Penetrating phenotype, perianal CD	Increased early endoscopic and clinical recurrence
Prior intestinal resection	Higher risk of further surgery and earlier recurrence
Extensive small-bowel resection	Increased recurrence and nutritional complications
Absence or delay of biologic prophylaxis	Higher endoscopic recurrence vs early anti-TNF therapy

CD: Crohn’s disease; TNF: Tumor necrosis factor.

Pouchitis: The principal long-term complication of IPAA

Pouchitis represents the most common complication following IPAA for UC, affecting up to 60% of patients within the first two years after surgery and with cumulative incidence increasing to 72% at 10 years. The condition manifests as inflammation of the ileal pouch mucosa and presents with increased stool frequency, urgency, abdominal cramping, and sometimes bloody stool discharge[11].

Acute pouchitis typically responds to antibiotic therapy, with ciprofloxacin and metronidazole representing first-line agents. However, approximately 15% of patients develop chronic pouchitis, either antibiotic-dependent (requiring continuous or recurrent antibiotic courses to maintain remission) or antibiotic-refractory (failing to respond to antibiotic therapy). The Pouchitis Disease Activity Index (PDAI) and modified PDAI (mPDAI) provide standardized assessment tools combining clinical, endoscopic, and histologic components[18,58].

Vedolizumab has emerged as the only biologic agent receiving regulatory approval for treatment of moderately to severely active chronic refractory pouchitis, based on results from the EARNEST trial demonstrating significantly higher mPDAI remission rates compared to placebo (31.4% vs 9.8% at week 14). Other biologic therapies including infliximab, adalimumab, and ustekinumab have shown promise in retrospective series and smaller studies. JAK inhibitors (tofacitinib, upadacitinib) and S1P receptor modulators (ozanimod) represent emerging options for chronic antibiotic-refractory pouchitis, particularly in patients failing multiple prior biologics[19,47,49,50].

Pouch failure and salvage surgery

Pouch failure-defined as need for permanent ileostomy, pouch excision, or functional failure rendering the pouch unusable-occurs in 5%-15% of patients following IPAA, representing a devastating complication given patients' typically strong preference to avoid permanent ostomy. Common causes include chronic pelvic sepsis, fistula formation (particularly pouch-vaginal fistulae in women), uncontrollable incontinence, and development of CD of the pouch[59].

Salvage surgery for failing pouches includes transabdominal pouch revision (either repairing and re-using the existing pouch or constructing a neo-pouch) and conversion to continent ileostomy. A comparative study found that repair/redo-IPAA preserved the pouch in 24.6% of patients with pouch failure, while conversion to continent ileostomy salvaged the pouch in 36.8%-together reducing the cumulative probability of permanent end ileostomy to 32.3%. Importantly, functional outcomes differ substantially, with patients after continent ileostomy conversion achieving complete continence and requiring only 4 or fewer evacuations daily, compared to higher evacuation frequencies and ongoing incontinence issues in many patients after redo-IPAA[19].

Quality of life assessment has become increasingly central to evaluating surgical outcomes in IBD. Systematic reviews examining quality of life in surgically treated IBD patients demonstrate that surgery significantly improved physical quality of life in 90% of patients. However, psychological and social challenges persisted in a substantial proportion, with 38% reporting body image issues and 34% experiencing social isolation. These findings underscore the importance of comprehensive preoperative counseling and postoperative psychological support[8,12,14,60,61].

Studies examining permanent ileostomy in IBD patients reveal a nuanced picture. While many patients adapt well to ostomy life and report improved quality of life compared to their preoperative disease state, challenges including fatigue and stoma-specific difficulties remain common. Development of a core outcome set for IBD patients with stomas has been undertaken to standardize outcome measurement and facilitate inclusion of this patient population in clinical trials[16,18,20,37,62].

For patients with IPAA, quality of life generally improves substantially compared to active colitis, though specific domains including nighttime evacuation frequency, fecal urgency, and occasional soilage may persist. Sexual function outcomes following IPAA have received increasing attention, with prospective studies examining both male genitourinary function and female sexual health outcomes[39,44,45,47,49,63].

Optimal management of IBD patients requiring surgery necessitates a multidisciplinary team approach integrating gastroenterologists, colorectal surgeons, dedicated IBD nurses, radiologists, pathologists, nutritionists, and psychologists. This collaborative model enables comprehensive preoperative optimization, coordinated medical-surgical decision-making, and seamless postoperative transition of care.

Emerging innovations in surgical IBD management include artificial intelligence-assisted decision-making, advanced robotic platforms, novel anastomotic techniques, and the integration of intraoperative technologies such as indocyanine green fluorescence angiography for anastomotic perfusion assessment. The development of reliable biomarkers for predicting surgical need, postoperative recurrence risk, and treatment response remains an active area of investigation[4,35,42,43,64-69].

CONCLUSION

Surgical intervention remains an indispensable component of comprehensive IBD management, providing definitive treatment for UC and effective, complication-directed control in CD. Contemporary surgical practice has evolved from extensive resections toward minimally invasive, bowel-preserving strategies that prioritize long-term function, quality of life, and reduction of cumulative disease burden.

Optimal outcomes in IBD surgery depend on careful patient selection, meticulous perioperative optimization, and close integration with advanced medical therapies within a multidisciplinary framework. Despite significant progress in operative techniques and postoperative care, challenges such as disease recurrence in CD and pouch-related complications following restorative procedures continue to limit long-term success.

Future advances in IBD surgery are likely to be driven by prospective outcome data, refined risk stratification, and the integration of emerging technologies-including artificial intelligence–assisted decision support, advanced robotic platforms, and predictive biomarkers-to better individualize surgical timing and technique. Continued collaborative research and multidisciplinary care will be essential to further improve durable disease control, functional outcomes, and patient-centered quality of life in this evolving therapeutic landscape.